Health-related quality of life outcomes for patients with transfusion-dependent beta-thalassemia treated with luspatercept in the BELIEVE trial

Maria Domenica Cappellini,1 Ali T. Taher,2 Antonio Piga,3 Farrukh Shah,4 Ersi Voskaridou,5 Vip Viprakasit,6 John B. Porter,7 Olivier Hermine,8,9 Ellis J. Neufeld,10 Alexis A. Thompson,11 Derek Tang,12 Peiwen Yu,13 Shien Guo,13 Jeevan K. Shetty,12 Dimana Miteva,12 Tatiana Zinger,12 Jay T. Backstrom,14 Esther Natalie Oliva15

1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy; 2Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon; 3Department of Clinical and Biological Sciences, University of Turin, Turin, Italy; 4Department of Haematology, Whittington Health NHS Trust, London, UK; 5Thalassemia and Sickle Cell Center of Laiko General Hospital, Athens, Greece; 6Siriraj Hospital, Mahidol University, Bangkok, Thailand; 7University College London Hospitals NHS Foundation Trust, London, UK; 8Necker Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France; 9Imagine Institute, INSERM Unité 1163, University of Paris, Paris, France; 10St. Jude Children’s Research Hospital, Memphis, TN, USA; 11Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, USA; 12Bristol Myers Squibb, Princeton, NJ, USA; 13Evidera, Waltham, MA, USA; 14Acceleron Pharma, Cambridge, MA, USA; 15Grande Ospedale Metropolitano Bianchi Melacrino Morelli, Reggio Calabria, Italy

Presentation 364
Presenting author disclosures

• Honoraria
  – Bristol Myers Squibb, Genzyme/Sanofi

• Membership on an entity’s board of directors
  – CRISPR Therapeutics, Genzyme/Sanofi, Novartis, Vifor Pharma
Introduction

• Patients with TD β-thalassemia may require long-term RBCT that can lead to iron overload and associated complications, which impact negatively on HRQoL\(^1\)

• A reduction in the number or frequency of RBCT, without other treatment modification, may increase anemia-related symptoms and thereby worsen HRQoL\(^1\)

• The international phase 3 BELIEVE study (NCT02604433) showed that the first-in-class erythroid maturation agent luspatercept provided clinically meaningful reduction in RBCT burden, but the impact of luspatercept on HRQoL is not yet understood\(^2\)

HRQoL, health-related quality of life; RBCT, red blood cell transfusions; TD, transfusion dependent.
Introduction (cont.)

• Luspatercept is a first-in-class erythroid maturation agent that binds to select TGF-β superfamily ligands to diminish Smad2/3 signaling and enhance late-stage erythropoiesis¹
  – Luspatercept was approved by the US Food and Drug² and European Medicines Agency³ for treatment of anemia due to β-thalassemia in adult patients who require regular RBC transfusions

ActRIIB, human activin receptor type IIB; IgG1 Fc, immunoglobulin G1 fragment crystallizable; P, phosphorylation; TGF-β, transforming growth factor beta.
**BELIEVE study design**

- **β-thalassemia** patients ≥ 18 years, requiring regular RBCT (6–20 RBC units in the 24 weeks prior to randomization with no > 35-day transfusion-free period during that time (N = 336)

1. Randomized 2:1
   - Luspatercept 1.0 mg/kg s.c. every 21 days + BSC (n = 224)
   - Placebo s.c. every 21 days + BSC (n = 112)

- Double-blind period (48 weeks)
  - May be titrated up to 1.25 mg/kg

- Study unblinding
  - Open-label (up to 5 years)
  - Post-treatment follow-up (3 years)

- Crossover from placebo to luspatercept permitted

---

**Notes:**
- B-thalassemia of Hb E/β-thalassemia (compound B-thalassemia with mutation and/or multiplication of α-globin genes was allowed); Patients could receive RBCT and ICT to maintain their baseline Hb level; The trial is fully enrolled and patients continue to receive treatment or follow-up.
- BSC, best supportive care; Hb, hemoglobin; ICT, iron chelation therapy; RBC, red blood cell; s.c., subcutaneous.
Objective

• To assess the effect of luspatercept plus BSC (including RBCT and ICT) versus placebo plus BSC on HRQoL in patients with TD β-thalassemia in the phase 3 BELIEVE study
Methods

• HRQoL was assessed at screening (≤ 4 weeks prior to first study dose) and every 12 weeks up to 48 weeks of treatment using:
  – The generic 36-item Short Form Health Survey (SF-36)\(^a\)
  – The thalassemia-specific Transfusion-dependent Quality of Life questionnaire (TranQol) which includes the domains Physical, Emotional, Sexual, Family, and School/Career Health\(^b,1,2\)

• The HRQoL evaluable population included all patients who completed the HRQoL assessment at screening and ≥ 1 post-screening assessment visit.

• Domains of the TranQol and SF-36 were considered complete if ≥ 75% and ≥ 50% of items, respectively, were answered at a given time point.

\(^{a}\)SF-36 consists of 8 domains and 2 component summary scales: Physical Component Summary (Physical Functioning, Role Physical, Bodily Pain, and General Health domains), Mental Component Summary (Vitality, Mental Health, Role Emotional and Social Functioning).

\(^{b}\)The TranQol has a total of 36 items across the 5 domains (Physical, 10 items; Emotional, 14 items; Sexual, 1 item; Family, 5 items; School/Career Health, 6 items). Possible scores for each domain and Total Score range from 0-100 with higher scores denoting better HRQoL.

Primary HRQoL endpoints

• The primary endpoint was change from baseline between groups up to Week 48 in:
  – SF-36 Physical Component Summary, Physical Functioning, and General Health
  – TranQol Total Score and Physical Health
  – Other domains were considered exploratory domains

• Changes from baseline were compared using ANCOVA models adjusting for baseline domain scores and geographic region
Exploratory HRQoL endpoints

- Exploratory analyses included comparison of clinically meaningful improvement in domain scores between patients on luspatercept achieving a clinical response and patients on placebo
- Clinical response to luspatercept was defined as:
  - ≥ 50% reduction in RBCT burden over any 12 weeks at Weeks 24 and 48
  - ≥ 33% reduction in RBCT burden over any 12 weeks at Weeks 24 and 48
  - Transfusion independence over any 8 or 12 weeks at Weeks 24 and 48
Patient demographics

• The HRQoL evaluable population was 211 patients (94.2%) in the luspatercept arm and 103 patients (92.0%) in the placebo arm

<table>
<thead>
<tr>
<th></th>
<th>Luspatercept (n = 211)</th>
<th>Placebo (n = 103)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), years</td>
<td>32.1 (10.8)</td>
<td>31.6 (9.9)</td>
</tr>
<tr>
<td>Sex, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>87 (41.2)</td>
<td>46 (44.7)</td>
</tr>
<tr>
<td>Region, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>North America and Europe</td>
<td>89 (42.2)</td>
<td>46 (44.7)</td>
</tr>
<tr>
<td>Middle East and North Africa</td>
<td>51 (24.2)</td>
<td>25 (24.3)</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>71 (33.6)</td>
<td>32 (31.1)</td>
</tr>
<tr>
<td>Baseline transfusion rate</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 6 units/12 weeks</td>
<td>107 (50.7)</td>
<td>52 (50.5)</td>
</tr>
<tr>
<td>&gt; 6 units/12 weeks</td>
<td>104 (49.3)</td>
<td>51 (49.5)</td>
</tr>
</tbody>
</table>

• HRQoL questionnaire compliance rates among patients still on treatment were > 87.5% for both questionnaires at Week 48

SD, standard deviation.
Baseline HRQoL scores for SF-36 domains

- Baseline HRQoL scores were similar to the US general population for most SF-36 domains

- Green circles denote highest-scoring domain scores compared with the general population

- Red circles denote domain scores which were impaired in the BELIEVE population

Mean T score

- Luspatercept
- Placebo

Baseline HRQoL scores were similar to the US general population for most SF-36 domains

- Green circles denote highest-scoring domain scores compared with the general population

- Red circles denote domain scores which were impaired in the BELIEVE population

aPrimary HRQoL endpoints.
MCS, Mental Component Summary; PCS, Physical Component Summary.
Changes in HRQoL primary endpoints up to Week 48

**SF-36 scores**
- There was no clinically meaningful change from baseline nor difference between treatment groups up to Week 48 in:
  - General Health
  - Physical Functioning
  - PCS

**TranQol scores**
- There was no clinically meaningful change from baseline nor difference between treatment groups up to Week 48 in:
  - Total Score
  - Physical Health
Correlation between RBCT and changes in HRQoL

SF-36 scores
• There was no significant correlation (r, P value) between the number of RBC units transfused and change in SF-36 Physical Functioning, Global Health, and PCS at Week 24 (0.02, \( P = 0.821 \); −0.09, \( P = 0.194 \); 0.01, \( P = 0.891 \); respectively) or Week 48 (0.08, \( P = 0.453 \); −0.18, \( P = 0.080 \); 0.06, \( P = 0.594 \); respectively).

TranQol scores
• There was no significant correlation (r, P value) between the number of RBC units transfused and change in TranQol Total Score and Physical Health at Week 24 (−0.09, \( P = 0.217 \); 0.02, \( P = 0.814 \); respectively) or Week 48 (0.05, \( P = 0.606 \); 0.04, \( P = 0.703 \); respectively).
Changes in HRQoL at Week 48 in luspatercept responders achieving reduction in RBCT

- Patients receiving luspatercept and achieving a ≥ 50% reduction in RBCT burden over any 12 weeks were significantly more likely than patients receiving placebo to have a clinically meaningful improvement in SF-36 PCS and Physical Functioning at Week 48.

*Within-patient clinically meaningful change from baseline was defined as 3.8–7.0-point improvement, based on the prespecified domain-specific cutoff values for the domains of the SF-36 questionnaire; **Within-patient clinically meaningful change from baseline was defined as a ≥ 4-point change for the TranQol total score and ≥ 0.5* SDs of the pooled domain score for other domains of the TranQol.

![Percentage of patients achieving clinically meaningful improvement in HRQoL at Week 48](image-url)
Changes in HRQoL at Week 24 in luspatercept responders achieving TI

- Patients receiving luspatercept and achieving TI for any 12 weeks were significantly more likely than patients receiving placebo to have a clinically meaningful improvement in SF-36 Physical Functioning and PCS at Week 24

![Graph showing percentage of patients achieving clinically meaningful improvement in HRQoL at Week 24](image)

- Within-patient clinically meaningful change from baseline was defined as 3.8–7.0-point improvement, based on the prespecified domain-specific cutoff values for the domains of the SF-36 questionnaire; 
- Within-patient clinically meaningful change from baseline was defined as a ≥ 4-point change for the TranQol total score and ≥ 0.5* SDs of the pooled domain score for other domains of the TranQol.
Limitations

• Some key benefits of luspatercept treatment, such as the impact of reducing RBCT visits on HRQoL, are not covered by the SF-36 and TranQol instruments

• Per study protocol, patients were still required to attend the clinic; therefore, any reduction in visits to receive RBCTs may not have been observed by the patient

• HRQoL was assessed at prespecified time points; however, patients were allowed to receive transfusions as needed at any time during the study, which could impact HRQoL assessments, particularly in key domains related to anemia (e.g. Physical Functioning, Physical Health)
Summary

- Luspatercept with BSC reduced RBCT burden while maintaining TranQol and SF-36 HRQoL scores through Week 48 compared with placebo
- HRQoL at baseline was similar to the general population
- Patients responding to luspatercept were more likely to achieve a clinically meaningful improvement in HRQoL than patients receiving placebo
- A higher proportion of luspatercept responders achieved clinically meaningful improvements in Physical Functioning and PCS compared with placebo
Acknowledgments

- This study was supported by Celgene, a Bristol-Myers Squibb Company, in collaboration with Acceleron Pharma
- All authors contributed to and approved the presentation; writing and editorial assistance was provided by Victoria Edwards, PhD, of Excerpta Medica, funded by Bristol Myers Squibb